Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, failing to significantly improve overall survival (OS) in patients who had relapsed following platinum-based chemotherapy. The trial examined the drug’s efficacy in two randomised groups, with one receiving Opdivo and the other using either topotecan or amrubicin. The primary endpoint was OS, while secondary endpoints included progression-free survival and objective response rates.
![Design thinking als contentmarketeer inzetten [voorbeelden & tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/11/business-team-working-in-a-start-up-office-2023-11-27-05-22-22-utc-1-80x60.jpg)
Reageer